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Myocarditis is an inflammation of the myocardium that can progress to a more severe 116 
phenotype of dilated cardiomyopathy. Three main harmful factors determine this 117 
progression: inflammation, cell death and oxidative stress. Lipoxins and their derivatives 118 
are endogenous pro-resolving mediators that induce the resolution of the inflammatory 119 
process. This study aims to determine whether these mediators play a protective role in a 120 
murine model of experimental autoimmune myocarditis (EAM) by treating with the 121 
lipoxin A4 analog BML-111. We observed that EAM mice presented extensive infiltration 122 
areas that correlated with higher levels of inflammatory and cardiac damage markers. 123 
Both parameters were significantly reduced in BML-treated EAM mice. Concordantly, 124 
cardiac dysfunction detected in EAM mice was prevented by BML-111 treatment. At the 125 
molecular level, we demonstrated that treatment with BML-111 hampered apoptosis and 126 
oxidative stress induction by EAM. Moreover, both in vivo and in vitro studies revealed 127 
that these beneficial effects were mediated by activation of Nrf2 pathway through 128 
CaMKK2-AMPKα kinase pathway. Altogether, our data indicate that treatment with the 129 
lipoxin derivative BML-111 effectively alleviates EAM outcome and prevents cardiac 130 
dysfunction, thus underscoring the therapeutic potential of lipoxins and their derivatives 131 
to treat myocarditis and other inflammatory cardiovascular diseases. 132 
 133 


















Myocarditis is an inflammation of the myocardium as a result of infection, autoimmune 149 
disease or cardiotoxic agents that can lead to acute heart failure, life threatening 150 
arrhythmias and even sudden death  (1). Cardiac function may rapidly deteriorate and 151 
patients become hemodynamically unstable requiring supportive therapy or cardiac 152 
transplantation. Regardless of its etiology, the initial acute inflammation may progress to 153 
tissue remodeling, fibrosis, and loss of myocardial architecture and contractile function. 154 
The latter chronic damage corresponds to the development of dilated cardiomyopathy 155 
(DCM)  (2). DCM overall incidence among myocarditis cases is not accurately known, 156 
but retrospective studies report that up to 50% of unexplained non-ischemic DCM cases 157 
exhibit histological evidence of myocarditis  (3). Therefore, it is important to detect the 158 
disease in its early stages to find therapeutic targets aiming to prevent the progression to 159 
a more advanced and irreversible cardiomyopathy. 160 
Experimental autoimmune myocarditis (EAM) mouse model, which is induced by 161 
immunizing mice with myocardial self-antigens, resembles the autoimmunological 162 
process of acute myocarditis and has been used to study the pathogenesis of clinical 163 
myocarditis. In this model, an inflammatory process is progressively developed, peaking 164 
at day 21 after first immunization, when the presence of extensive areas of infiltrated 165 
immune cells is maximum  (4). These cells migrate to the organ releasing high levels of 166 
pro-inflammatory mediators (IL-1β, IL-6, TNFα…) that initiate the inflammatory 167 
response  (5). Afterwards, the accumulation of these harmful molecules can cause 168 
metabolic alterations in cardiac cells as well as increasing the release of reactive oxygen 169 
species (ROS)  (6). This adverse scenario induces apoptosis on cardiac cells, eventually 170 
driving to a mechanic overload in the heart that cells compensate by increasing their size 171 
and thus generating a hypertrophic phenotype  (7). When this situation is maintained, it 172 
drives to organ dysfunction causing the release of cardiac damage mediators like 173 
natriuretic peptides —BNP and ANP (8)— or galectin 3  (9). Moreover, some research 174 
groups have described the appearance of fibrotic areas in the affected hearts that could 175 
aggravate cardiac dysfunction. The onset of fibrosis in EAM model seems to be mainly 176 
modulated by transforming growth factor beta-1 (TGF-β1) and collagen overexpression  177 
(10).  178 
Current therapies for myocarditis or DCM are mainly based on anti-inflammatory and 179 




diuretics. However, their outcome is not completely favorable and patients do not exhibit 181 
full recovery.  Therefore, ongoing research is focusing on the design of more efficient 182 
and specific therapies (i.e., Registry of Cell Therapy in Non-Ischemic Dilated 183 
Cardiomyopathy (RECORD); ClinicalTrials.gov). Specialized pro-resolving lipid 184 
mediators (SPMs) are endogenous molecules that represent a promising alternative thanks 185 
to their pleiotropic anti-inflammatory actions  (11). It has been broadly described that 186 
these SPMs limit the recruitment of neutrophils, increase the production of anti-187 
inflammatory mediators and promote the clearance of cell debris  (12, 13). Among them, 188 
the most studied are lipoxins, which are endogenously released in the inflammatory area 189 
to allow for the recovery of tissue homeostasis  (14). However, due to its rapid 190 
inactivation and short half-life, more stable and effective analogs like BML-111 [5(S), 191 
6(R), 7-trihydroxyheptanoic acid methyl ester] have been designed, exerting anti-192 
inflammatory and pro-resolving effects equivalent to lipoxins in several pathological in 193 
vivo models with a prolonged action  (15). In fact, it has been already demonstrated that 194 
BML-111 reduces inflammation in psoriasis  (16), ischemia-reperfusion injury  (17), 195 
acute lung injury  (18) or arthritis  (15) animal models. Furthermore, ongoing clinical 196 
trials are evaluating the protective role of lipoxin analogs in asthmatic children with acute 197 
episodes through inhalation  (19) or in gingivitis (ClinicalTrials.gov: NCT02342691). 198 
Despite the broad number of studies analyzing the beneficial effects of SPMs in human 199 
pathologies, their role in cardiovascular diseases (CVDs) has only been recently 200 
addressed.  201 
Since myocarditis-affected hearts are characterized by exacerbated levels of oxidative 202 
stress that eventually lead to cardiac cells apoptosis, the transcription factor Nrf2 (nuclear 203 
factor erythroid 2-related factor 2) plays an important role as a major regulator of the 204 
expression of antioxidant genes  (20). These include heme oxygenase 1 (HO-1), 205 
NAD(P)H quinone oxidoreductase 1 (NQO1), catalase and peroxiredoxin-1 (PRDX-1). 206 
Nrf2 stability and activation is mainly mediated by Keap1 (Kelch-like ECH associated 207 
protein-1), which interacts with Nrf2 and inhibits its nuclear translocation  (21). In 208 
addition, Nrf2 activation can also be modulated by post-translational modifications, 209 
particularly through phosphorylation by different kinases like AMPKα (AMP-activated 210 
protein kinase alpha)  (22). AMPKα induces nuclear sequestration of Nrf2 by 211 
phosphorylating its nuclear exportation sequence (NES)  (23).  Upstream to AMPKα, 212 




tightly associated with cardiac signaling  (24), recent studies indicate that CaMKK2 may 214 
play a significant role mediating AMPKα activation in response to changes in calcium 215 
efflux  (25) or during ischemic complications  (26). Since these kinases are sensors to cell 216 
stress, they could be activated in a cardiac harmful scenario modulating Nrf2 pathway 217 
thus controlling oxidative stress and cell death.  218 
Several works have demonstrated the modulation of Nrf2 by lipoxins or their derivatives 219 
as one of the main mechanisms behind their beneficial effects in pathological models like 220 
intestinal  (27) and renal  (28) ischemia/reperfusion damage, in LPS-induced mouse acute 221 
lung injury  (29) or venous thromboembolism  (30). Nevertheless, the modulation of this 222 
antioxidant pathway in cardiac pathologies remains to be further investigated since it may 223 
be responsible, at least in part, for the beneficial effects of SPMs observed in CVDs. In 224 
addition, growing evidence indicates that decreased Nrf2 activity contributes to oxidative 225 
stress induction in the heart, favoring the pathophysiology of cardiovascular disorders 226 
found in obesity, diabetes mellitus, and atherosclerosis  (31). Therefore, compounds 227 
capable of modulating cardiac Nrf2 activation could be effective in several CVDs. In the 228 
present study, we performed an EAM murine model where we investigated the regulatory 229 
role of BML-111 in anti-inflammatory and antioxidant cardiac pathways. This study 230 
provides new insights for the development of therapeutic targets driven to improve 231 
prognosis and treatment of CVDs patients.  232 
 233 
2. MATERIAL AND METHODS. 234 
2.1. Animals, immunization and treatment. BALB/c mice from Charles River 235 
Laboratories (Wilmington, MA, USA) were housed in the Animal Care Facility from the 236 
Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM, CSIC-UAM) and were 237 
provided food and water ad libitum, under standard conditions. All experimental 238 
procedures were reviewed and approved by the Animal Ethics Committee of the IIBM 239 
and Comunidad Autónoma de Madrid (PROEX 144/17) and were in accordance with the 240 
European Legislation.  241 
Before the procedure, all mice were anesthetized by inhalation of 2% isoflurane and 2 242 
l/min oxygen flow rate to minimize animal stress. Disease was induced in 8 week-old 243 
female mice by subcutaneous immunization in both dorsal flanks of the animal at days 0 244 
and 7 with 350 µg of cardiac myosin previously isolated following the protocol described 245 




Adjuvant containing Mycobacterium tuberculosis H37RA (5 mg/ml). Control groups 247 
were injected with physiological saline solution instead of myosin. BML-111 (Enzo 248 
Lifescience (NY, USA), 10 mg/ml) or its vehicle (ethanol) were intraperitoneally injected 249 
at 1 mg/kg from day 7 to day 21 in the corresponding groups. Thus, four experimental 250 
groups were established: Control+Vehicle (Control+Veh), Control+BML-111 251 
(Control+BML), Myosin+vehicle (EAM+Veh) and Myosin+BML-111 (EAM+BML). At 252 
day 21, all mice were anesthetized again with 2% isoflurane and 2 l/min oxygen flow rate 253 
to perform echocardiographic study. Then, blood was obtained, and mice were sacrificed 254 
by cervical dislocation. Body weight and tibial length were recorded. Finally, hearts were 255 
carefully removed from the chest, cleaned, weighed and processed. 256 
2.2. Transthoracic echocardiography. M-mode echocardiography was employed to 257 
evaluate cardiac function. Mice were anesthetized with 2% isoflurane and 2 l/min oxygen 258 
flow rate; the chest of the mouse was shaved, and warm ultrasound transmission gel was 259 
used to obtain an optimal image quality. Mouse hearts were analyzed with a high-260 
frequency micro-ultrasound system (Vivid Q, General Electric Healthcare, IL, USA). 261 
Parasternal short-axis-view images of the heart were recorded using a 30-MHz RMV scan 262 
head in B-mode to allow M-mode recordings by positioning the cursor in the parasternal 263 
short-axis view perpendicular to the interventricular septum and posterior wall of the left 264 
ventricle. Left ventricle ejection fraction and fractional shortening were determined using 265 
the on-site software cardiac package (GE Healthcare (Chicago, IL, USA)). 266 
2.3. BNP levels determination. Plasmatic BNP levels were determined using the 267 
RayBio® Immunoassay (Raybiotech, Inc (GA, USA), #EIA-BNP-1) following the 268 
manufacturer´s instructions. 269 
2.4. Immunohistochemistry. Sections were fixed in fresh 4% paraformaldehyde and 270 
embedded in paraffin, cut in a microtome and stained with hematoxylin/eosin. 271 
Histological examination was performed with a Zeiss Axiophot microscope connected to 272 
a digital camera. Three sections per mouse were examined blindly by two different 273 
investigators and the severity of disease was qualitatively scored according to Dallas 274 
classification with grades from 0 to 4 (0=no inflammatory infiltrates; 1=small foci of 275 
inflammatory cells between myocytes; 2=larger foci of 100 inflammatory cells; 3=more 276 
than 10% of cross-section involved; and 4=more than 30% of cross-section involved) 277 




2.5. Immunofluorescence. Heart sections were dehydrated in a sucrose gradient, fixed in 279 
4% paraformaldehyde and then frozen in OCT reagent. Tissues were then cut in a 280 
cryostat; sections were picked up on a glass slide and maintained at -80°C. After blocking 281 
with 5% BSA + 10% normal goat serum + 0.3% Triton X-100 for 1 h at room temperature,  282 
heart slides were incubated with the corresponding primary antibodies at 4°C overnight: 283 
CD68 (Novus Biologicals (Centennial (CO, USA), 100-683), Ly-6G (Novus Biologicals 284 
600-1387), RORγT (Thermo Fisher (Waltham, MA, USA) 14-6988-80), cleaved-caspase 285 
3 (Cell Signaling (Danvers, MA, USA) #9664), α-actinin (Sigma (San Luis, MO, USA) 286 
#A7811), 8-OHdG (Abcam, Cambridge, UK #62623), MDA (Abcam #6463) or Keap1 287 
(Thermo Fisher #1F10B6). Samples were incubated with secondary antibodies combined 288 
with Alexa Fluor 488, 546, 647 (Molecular Probes (Eugene, OR, USA)) for 2 h 1:500 and 289 
then DAPI (Molecular Probes #D1306) 1:500 for 10 min at room temperature, gently 290 
washing with PBS1X between incubations. Finally, sections were washed again and 291 
coverslips were mounted in ProLong® Gold Antifade reagent (Life Technologies, 292 
(Carlsbad, CA, USA)) and examined using a confocal microscope Leica PCS SP5. Values 293 
of intensity fluorescence were determined with Image J software. 294 
2.6. TUNEL assay. Heart sections were stained using the in situ cell detection kit with 295 
fluorescein (Roche (Basel, Switzerland) #11684795910) following the manufacturer´s 296 
instructions.  297 
2.7. RNA isolation and qPCR. RNA was extracted from hearts using TRI Reagent® 298 
solution (Ambion (Austin, TX, USA)) and 250 ng were reverse-transcribed into cDNA 299 
using the High-capacity cDNA reverse transcription kit (Applied Biosystems (Foster 300 
City, CA, USA) #4368813). Then, PCR reaction was performed with this template cDNA 301 
at 2,5 ng/µl adding Power SYBR Green PCR Master Mix (Applied Biosystems 302 
#4367659) and the specifics primers (Table 1) in a 7900HT Fast real time PCR system 303 








Gene Forward Reverse 
Anp ATTGACAGGATTGGAGCCCAGAGT TGACACACCACAAGGGCTTAGGAT 
Col1a1 AATGGCACGGCTGTGTGCGA AGCACTCGCCCTCCCGTCTT 
Col3a1 CTGTAACATGGAAACTGGGGAAA CCATAGCTGAACTGAAAACCACC 
Il1b AGAAGCTGTGGCAGCTACCTG GGAAAAGAAGGTGCTCATGTCC 
Il6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 
Tgfb1 CCACCTGCAAGACCATCCAC CTGGCGAGCCTTAGTTTGGAC 
Tnfa CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC 
Rplp0 AGATGCAGCAGATCCGCAT GTTCTTGCCCATCAGCACC 






2.8. HL-1 cell culture. Cells were maintained in pre-coated flasks with gelatin/fibronectin 314 
using complete Claycomb medium (Sigma #51800C) with 10% FBS following the 315 
distributor instructions. 316 
2.9. Preparation of whole protein cardiac/cell extracts. Hearts were homogenized in a 317 
buffer containing sucrose 320 mM and protease and phosphatase inhibitor cocktails 318 
(Sigma) at pH7. Cells were homogenized in a buffer containing 10 mM Tris-HCl pH7.5; 319 
1 mM MgCl2, 1 mM EGTA, 10% glycerol and 0.5% CHAPS with the same inhibitors. 320 
Both homogenates were vortexed for 45 min and centrifuged (13,000g, 15 min at 4°C) 321 
and supernatants were frozen and stored at −80°C for western blot analysis. Protein 322 
concentration was determined by Bradford assay (Bio-Rad (Hercules, CA, USA).  323 
2.10. Preparation of nuclear and cytosolic cell extracts. Cardiac tissue/cells were 324 
homogenized in 0.25 M sucrose buffer with protease and phosphatase inhibitor cocktails 325 
(Sigma), using a Dounce tissue grinder and maintained 30 min on ice. Solution was 326 
centrifuged at 800g 15 min at 4°C to separate cytosolic extract (supernatant) and nuclear 327 
extract (pellet). Cytosolic extract was serially centrifuged at 800g 10 min and then at 328 
11,000g 10 min both at 4°C. Supernatant was then precipitated by treating with cold 329 
acetone for 1 h at -20°C and centrifuging at 12,000g 5 min at 4°C. Pellet obtained was 330 
resuspended in 150 µl (cells) or 500 µl (tissue) of sucrose buffer. Nuclear extract was 331 
washed with sucrose buffer and centrifuged first at 500g 15 min and then at 1,000g 15 332 
min, both at 4°C. Pellet obtained was resuspended in 200-500 µl of a buffer containing 333 
20% glycerol and 1% Triton X-100, lysed by passing through a 20G needle, and then 334 
centrifuged at 9,000g 30 min at 4°C. Supernatant obtained represented nuclear fraction. 335 
Both cytosolic and nuclear extracts were maintained at -20°C for western blot analysis. 336 
Protein concentration was determined by Bradford assay (Bio-Rad).  Lamin B was used 337 
as a nuclear marker to ensure an appropriate purification of each fraction. 338 
2.11. Western blot. Equal amounts of protein (20-60 μg) from each fraction obtained were 339 
loaded into 8-12% SDS-PAGE. Proteins were size fractionated, transferred to a PVDF 340 
membrane (Bio-Rad) and, after blocking with 5% non-fat dry milk, incubated with the 341 
corresponding antibodies (Table 2). Blots were developed by ECL protocol and different 342 
exposition times were performed for each blot to ensure the linearity of the band 343 
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 346 
Target Distributor Reference 
AMPKα Cell Signaling 5832 
P-AMPKα Cell Signaling 2535 
Bcl2 Cell Signaling 2870 
CaMKK2 Cell Signaling 16810 
Catalase Millipore (Burlington, MA ,USA) 219010 
EndoG Santa Cruz Biotech. (Dallas, TX, USA) sc-365359 
Galectin-3 Santa Cruz Biotech. sc-32790 
GAPDH Ambion AM4300 
HO-1 Millipore AB1284 
Keap-1 Thermo Fischer scientific PA5-34454 
Lamin B Santa Cruz Biotech. sc-6217 
NQO1 Cell Signaling 3187 
Nrf2 Homemade Dr.Cuadrado´s lab ---- 
PRDX-1 Santa Cruz Biotech. 137222 
TNFα Abcam ab-8348 
Vinculin Cell Signaling 13901 
  Table 2. Specific antibodies used in western blot assays.       347 
 348 
2.12. Statistical analysis. Values in graphs correspond to the mean ± standard deviation 349 
(SD). In box and whiskers diagram, boxes represent median and interquartile range and 350 
whiskers represent maximum and minimum values. Statistical significance was estimated 351 
with two-tailed Student t test for unpaired observations and one-way ANOVA for 352 
multiple comparisons followed by Tukey´s range test as indicated under each figure. All 353 
analyses were performed using GraphPad Prism Software. 354 
 355 
3. RESULTS. 356 
3.1. EAM model characterization.  357 
Since EAM is an inflammatory model of cardiac damage, we first determined the 358 
presence of immune infiltrates in the heart by histological staining, quantifying them 359 
according to Dallas criteria  (33) (Fig. 1a). We determined that EAM+vehicle group 360 
(hereinafter referred to as EAM) had higher infiltration score than both controls, which 361 
was significantly lower in BML-treated EAM group (Fig. 1b). We next characterized the 362 
immune cells in the infiltrated area by immunofluorescence. Compared to control groups 363 
that present very low levels of immune cells, hearts from EAM mice animals showed 364 




(6.4%) and RORγT+ TH17 lymphocytes (9.8%) (Supp. Fig. 1). These values were 366 
significantly reduced by more than half in hearts from BML-treated EAM animals. Since 367 
a severe immune infiltration was evident in EAM hearts, we analyzed cardiac mRNA 368 
levels of Il1b, Il6 and Tnfa as classic pro-inflammatory cytokines by qPCR. As expected, 369 
EAM group exhibited significantly augmented levels of these cytokines that were 370 
decreased in BML-treated EAM animals in the case of Il1b and Tnfa (Fig. 1c). 371 
Accordingly, when we determined the protein levels of inflammatory markers in the 372 
heart, we detected enhanced protein expression of Galectin-3 and TNFα in EAM group 373 
compared to both controls, which was significantly reduced in BML-treated EAM mice 374 
(Fig. 1d). These results indicate that BML-111 treatment averted expression of pro-375 
inflammatory mediators and blocked the recruitment of immune cells to the affected 376 
hearts. 377 
The inflammatory phenotype associated to EAM produces cardiac dysfunction. Thus, we 378 
carried out echocardiographic studies to determine cardiac function in each experimental 379 
group (Table 3). Whereas vehicle and BML-treated control groups showed normal values 380 
for the analyzed parameters, EAM group exhibited significantly decreased ejection 381 
fraction (EF) and fractional shortening (FS) and augmented levels of left ventricle end-382 
systolic diameter (LVESD) compared to control groups. All these functional parameters 383 
indicate the appearance of ventricular dysfunction in EAM mice that was significantly 384 
prevented in BML-treated EAM mice. Other factors, such as left ventricle end-diastolic 385 




EF (%) FS (%) LVESD (mm) LVEDD (mm) HR (bpm) N 
Control + Veh 70.3 ± 8.7 41.3 ± 7.1 1.5 ± 0.1 2.6 ± 0.6 333.7 ± 43.8 15 
Control + BML 67.2 ± 4.9 36.4 ± 10.9 1.9 ± 0.2 2.9 ± 0.6 308.7 ± 31.7 19 
EAM + Veh 47.6 ± 3.2 *** 20.9 ± 3.4 *** 2.1 ± 0.1 *** 2.6 ± 0.4 304.1 ± 44.7 22 
EAM + BML 66.6 ± 4.9 ### 39.2 ± 13.4 ### 1.6 ± 0.1 ### 2.7 ± 0.7 306.3 ± 36.1 17 
Table 3. Cardiac function parameters obtained from echocardiography. Values represent mean ± SD. Statistical 388 
significance was determined using one-way ANOVA followed by Tukey´s multiple comparisons test for multiple 389 
groups comparisons. ***P≤0.001 vs. Control+Veh; ###P≤0.001 vs. EAM+Veh group. 390 
 391 
In this experimental model, cardiac dysfunction could be associated to the development 392 
of hypertrophy in the hearts of affected animals. Indeed, we observed that EAM mice 393 
exhibited higher heart weight (HW) to body weight (BW) or tibial length (TL) ratios (Fig. 394 




values did not show any difference among groups (data not shown). In the same line, we 396 
determined increased levels of cardiac damage and hypertrophy markers in EAM mice, 397 
concretely plasmatic BNP (Fig. 2c) and cardiac Anp mRNA expression (Fig. 2d). Both 398 
parameters were significantly lower in BML-treated EAM mice. These results 399 
demonstrate that BML-111 treatment is able to prevent cardiac dysfunction in EAM-400 
induced animals in part by reducing their associated cardiac hypertrophy. Besides cardiac 401 
hypertrophy, fibrosis development, which can also severely impair cardiac function, has 402 
been described to occur in EAM model at day 21 as well  (34). In our case, EAM animals 403 
presented higher cardiac mRNA levels of the classic fibrotic markers TGF-β1 (Tgfb1) or 404 
collagen 1 (Col1a1) and 3 (Col3a1) (Fig. 2e) that were significantly lesser in the case of 405 
TGF-β1 and collagen 1 in BML-treated EAM mice.  406 
3.2. Effects of BML-111 on cardiac cells apoptosis. 407 
Cardiac dysfunction can be associated to increased cardiomyocyte death, which 408 
eventually debilitates the contractive capacity of the heart. We determined that in EAM 409 
group, hearts presented significantly higher percentage of TUNEL-positive nuclei that 410 
were reduced upon BML-111 treatment (Fig. 3a). Accordingly, we also detected higher 411 
expression of the classic apoptotic effector cleaved-caspase 3 by immunofluorescence in 412 
EAM group that were significantly lower in BML- treated EAM mice (Fig. 3b). As these 413 
results indicate the activation of cardiomyocytes apoptosis, we next analyzed the levels 414 
of apoptotic proteins in cardiac tissue by western blot (Fig. 3c). We observed that the 415 
levels of the anti-apoptotic protein Bcl-2 were reduced in EAM animals, and BML-111 416 
treatment maintains higher levels of this protein despite not reaching statistical 417 
significance. Conversely, the pro-apoptotic protein endonuclease G (EndoG) levels were 418 
increased in EAM animals and were significantly reduced in BML-treated EAM mice. 419 
This protein induces apoptosis via DNA degradation when translocating from the 420 
mitochondria to the nucleus under oxidative stress conditions. Therefore, BML-111 421 
appears to ameliorate EAM outcome in part by mitigating cardiac cell death, thus 422 
improving cardiac functionality. 423 
3.3. Effects of BML-111 in the cardiac oxidative stress development: Nrf2 pathway. 424 
Hearts from EAM animals are also exposed to elevated levels of oxidative stress that 425 
overwhelm the capacity of antioxidant systems to cope with this severe inflammatory 426 
scenario. This stress can exacerbate inflammation aggravating the autoimmune reaction 427 




cardiac remodeling, eventually leading to cardiomyopathies. At the cellular level, this 429 
oxidative damage can permanently affect membrane lipids, proteins, and even DNA. 430 
Thus, we first characterized the cardiac presence of a broadly described biomarker of 431 
oxidative DNA damage, 8-hydroxy-2'–deoxyguanosine (8-OHdG) by fluorescence 432 
techniques (Fig. 4a). We detected significantly higher levels of 8-OHdG in EAM mice 433 
hearts compared to controls and BML-111 treatment significantly prevented these. We 434 
additionally evaluated malondialdehyde (MDA) staining for lipid peroxidation, which 435 
also exhibited higher levels in hearts from EAM mice (Fig. 4b). Despite a certain 436 
variability, MDA levels also tended to reduce in BML-treated EAM mice (Fig. 4b).  437 
Since it is known that SPMs can induce the activation of the Nrf2 transcription factor, the 438 
“master regulator” of oxidative stress resistance, we hypothesized that the antioxidant 439 
effect of BML-111 could be based on an induction of the Nrf2 pathway. First, we 440 
analyzed the protein levels of the main Nrf2 inhibitor, Keap1, in cardiac tissue by 441 
immunofluorescence (Fig. 4c). We observed increased positive staining in EAM mice 442 
compared to both controls that was reduced in BML-treated EAM animals. These results 443 
were confirmed by western blot analysis of Keap1 protein levels (Fig. 4d). These data 444 
suggested that BML-111 treatment could mitigate oxidative stress by activating Nrf2 445 
pathway. To deeply analyze the involvement of Nrf2 in the BML-mediated beneficial 446 
effects, we performed a set of experiments inoculating additional mice with BML-111 for 447 
shorter periods of time (1-6 h) and quantified Nrf2 nuclear protein levels in cardiac tissue 448 
(Fig. 5a). In these experiments, we observed that BML-111 significantly induced the 449 
translocation of Nrf2 into the nucleus, particularly at 1 and 6 h. Moreover, longer 450 
treatment with BML-111 for 24h significantly upregulated several of Nrf2 main 451 
antioxidant targets: HO-1, NQO1, catalase and PRDX-1 (Fig. 5b). All these data 452 
demonstrate that the cardioprotective effect of BML-111 is in part based on an induction 453 
of the antioxidant response via activation of the Nrf2 pathway.  454 
3.4. Molecular analysis of the signaling pathway activated in the heart by BML-111. 455 
To elucidate the molecular pathway involved in this Nrf2 induction, we performed some 456 
additional in vitro experiments using the murine cardiac cell line HL-1. Once verified that 457 
in these cells Nrf2 nuclear levels were also significantly increased after BML-111 458 
treatment, we analyzed upstream signaling in vitro. It has been described that stress can 459 
directly activate CaMKK2 in cardiac cells  (35). This protein is capable of activating 460 




(22). When HL-1 cells were treated with BML-111 for short periods of time, we detected 462 
an early induction of CaMKK2 at 5 min followed by an increased phosphorylation of 463 
AMPKα from 30 min to 2 h, which agrees with CaMKK2-AMPKα-Nrf2 signaling 464 
pathway (Fig. 6a). To further confirm the implication of AMPKα in BML-111-mediated 465 
Nrf2 activation in this model, we treated HL-1 cells with compound C, a potent, selective 466 
and reversible inhibitor of AMPK activity  (36). We confirmed that compound C 467 
effectively inhibits AMPKα since phosphorylation of ACC (acetyl-CoA carboxylase), 468 
one of the main targets of AMPKα kinase activity, was abolished (data not shown). Then, 469 
we observed that Nrf2 nuclear translocation induced by BML-111 treatment was 470 
significantly inhibited upon compound C treatment (Fig 6b). In conclusion, these data 471 
confirm that the cardioprotective effect of BML-111 appears to be regulated by the 472 
sequential activation of the CaMKK2-AMPKα axis. 473 
 474 
4. DISCUSSION. 475 
Myocarditis is an inflammatory disease of the myocardium characterized by the presence 476 
of immune infiltrates and apoptotic cardiomyocytes in cardiac muscle. Importantly, 477 
affected patients often progress to a more severe form of the disease termed DCM that, 478 
once developed, it is irreversible in the broad majority of cases. Thus, the design of 479 
efficient therapeutic approaches is still needed to reduce the progression from cardiac 480 
harmful initial conditions to DCM.  481 
Since inflammation plays an important role in CVDs, SPMs arise as promising 482 
endogenous targets to design a new therapy due to their broadly demonstrated anti-483 
inflammatory and pro-resolving properties  (37). In recent years, SPMs have been already 484 
shown to have protective role in major CVDs in murine models where they are able to 485 
improve cardiac function and reduce both efferocytosis and pro-inflammatory cytokines 486 
release, improving the pathological phenotype. Accordingly, in the present study we 487 
provide experimental evidence that the lipoxin A4 analog BML-111 decreases EAM 488 
severity in mice by reducing both inflammatory cell infiltration and the expression of 489 
several pro-inflammatory cytokines. In fact, BML-111 was able to prevent the increase 490 
of both IL-1β and TNFα levels. However, it was unable to modify IL-6 levels, possibly 491 
due to its role as a pleiotropic cytokine with a dual role in inflammation. There exists 492 
evidence that IL-6 can be both protective or pathogenic depending on the kinetics of the 493 




inflammatory response and fibrosis development in several autoimmune disease models  495 
(39). In our study the maintenance of high cardiac levels of IL-6 after BML-111 treatment 496 
can be considered as a protective response since this cytokine protects myocytes against 497 
oxidative stress and its signaling induces an anti-apoptotic program  (40). 498 
Furthermore, we here demonstrated that BML-111 treatment prevents cardiac 499 
dysfunction of EAM mice. In the same line, BML-treated EAM mice exhibited reduced 500 
levels of cardiac damage markers like plasmatic BNP, which have been reported to be 501 
inversely related to LXA4 levels in chronic heart failure patients  (41), and cardiac ANP 502 
expression. Interestingly, our data suggest that despite cardiac inflammation and 503 
dysfunction are both evident in EAM mice, fibrosis contribution to the final phenotype is 504 
minimal. Indeed, implication of fibrosis in EAM development is still controversial due to 505 
the heterogeneity of the data, with some groups reporting the presence of fibrotic areas in 506 
EAM hearts at day 21  (34, 42), whereas other groups consider that fibrosis development 507 
does not become apparent until day 54  (43, 44). On the other hand, BML-111 treatment 508 
also managed to reduce cardiac hypertrophy in EAM mice as observed by the reduction 509 
of both HW/BW or HW/TL ratios. These results unveil the ability of SPMs to prevent 510 
pathological cardiac hypertrophy and requires further investigation.  511 
The appearance of cell death foci of cardiac cells in affected hearts is another important 512 
factor contributing to cardiac dysfunction in CVDs. Several studies have demonstrated 513 
that SPMs are capable to modulate cell death pathways, acting as pro- or anti-apoptotic 514 
mediators depending on the cell type  (45, 46). Indeed, it has been shown that elevated 515 
protein levels of LXA4 can be related to higher cardiomyocyte survival by modulation of 516 
PI3K/Akt pathway  (47). This pathway has also been related to the anti-inflammatory 517 
effects of LXA4 observed in the EAM model  (48). However, we have demonstrated for 518 
the first time that, in addition to their anti-inflammatory actions, BML-111 also reduced 519 
the number of apoptotic areas in EAM hearts and this effect is associated to a significant 520 
reduction in cardiac levels of the apoptotic proteins EndoG and caspase 3. These results 521 
are in accordance with Zhao et al., who demonstrated that LXA4 can regulate cardiac 522 
mRNA levels of caspase 12, which acts upstream in caspase 3 activation pathway, in an 523 
ischemia-reperfusion model  (49). Overall, the ability of BML-111 to reduce cardiac cell 524 
death preserves appropriate heart functioning, decreasing the consequent development of 525 
fibrotic and non-functional regions that impairs cardiac contractility and seriously 526 




Furthermore, oxidative stress, defined as an exacerbated production of ROS affecting 528 
cells, tissue and organ homeostasis, has been shown to play an important role in the 529 
pathophysiology of CVDs  (50). In this context, it has been demonstrated that SPMs 530 
possess an antioxidant effect in many pathological scenarios, mainly through an induction 531 
of the transcription factor Nrf2, considered as the “redox guardian” of the cells. 532 
Nonetheless, little is known about this modulation in the cardiac context, with only Chen 533 
et al. demonstrating that LXA4 was able to protect cardiomyocytes against 534 
hypoxia/reoxygenation injury mainly by activating the Nrf2 pathway  (51). Here we 535 
determined that BML-111 is able to reduce the DNA damage associated to oxidative 536 
stress in EAM model also through activation of Nrf2 pathway as well as its antioxidant 537 
targets. Furthermore, we detected that this BML-associated cardiac induction of Nrf2 is 538 
mediated by Keap1, whose modulation by SPMs had been only demonstrated in intestinal  539 
(27) or lung injury animal models  (52). 540 
Our study demonstrates the contribution of the antioxidant Nrf2 pathway to the improved 541 
cardiac phenotype observed in SPMs-treated animals upon EAM induction. Moreover, 542 
we have looked into the molecular signaling mediated by SPMs in the heart. By using an 543 
in vitro model we determined that Nrf2 upstream signaling is regulated by the sequential 544 
activation of CaMKK2-AMPKα kinase cascade in cardiomyocytes. The interaction 545 
between SPMs and AMPKα signaling had been already proposed in adipose tissue  (53), 546 
where RvD1 treatment in db/db mice increased AMPKα phosphorylation. However, its 547 
role in obesity remains controversial as Borgesson et al. thereafter showed that, in an 548 
obesity-induced adipose inflammatory model, lipoxins can exert their function 549 
independently of AMPKα  (54).  Regarding cardiac tissue, previous studies have 550 
described that the flavonoid butin induced the modulation of the Nrf2 antioxidant 551 
pathway through AMPKα  (55). Interestingly, we have demonstrated for the first time 552 
that SPMs are able to activate the same molecular signaling that this flavonoid in 553 
cardiomyocytes, highlighting the potent antioxidant role of these pro-resolution 554 
mediators.  555 
In summary, myocarditis is an extremely complex immune-mediated process. Despite the 556 
growing body of knowledge about its pathogenesis, the specific factors implicated in 557 
disease development in patients remain unknown. Indeed, myocarditis progression to 558 
DCM is still unpredictable in clinical practice. Advances exist in therapeutics, but still 559 




suboptimal results. Future basic and translational studies might provide new insights in 561 
the pathogenesis of myocarditis leading to development of better diagnostic tools. Among 562 
them, SPMs, which we have demonstrated to have a protective effect on EAM cardiac 563 
model attenuating both inflammation, cardiomyocyte death and cardiac oxidative stress, 564 
arise as a potential alternative with low adverse effects. Thus, since this harmful scenario 565 
is common to the majority of CVDs, these lipid mediators represent a promising targeted 566 
therapeutic option in the future, mainly contributing to improve their initial stages and to 567 
limit the progression to a more harmful and irreversible phenotype. 568 
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Figure Legends. 760 
Figure 1. Hearts from BML-111 treated-mice presented lower inflammatory levels 761 
than EAM-mice and a lesser degree of immune infiltration (a) Representative images 762 
of histological analysis of immune cell infiltration in cardiac tissue from mice of each 763 
experimental group and the corresponding quantification (b) following Dallas criteria. 764 
Objective lens 20X. n≥20. Boxes represent median and interquartile range; whiskers 765 
represent maximum and minimum values. (c) Cardiac mRNA levels of several pro-766 
inflammatory mediators (Il1b, Il6 and Tnfa) determined by qPCR. Graphs represent fold 767 
induction (FI) of each experimental group using Rplp0 as endogenous control. n≥7 (Il1b), 768 
n≥13 (Il6), n≥18 (Tnfa). (d) Representative western blot images (left panel) and their 769 
corresponding quantification (right panel) of Galectin-3 and TNFα protein levels in 770 
cardiac tissue from all experimental groups. Normalization was performed using GAPDH 771 
as reference. n≥7 (Galectin-3), n≥6 (TNFα). Graphs represent mean ± SD. Dots represent 772 
individual data points. Statistical significance was determined using one-way ANOVA 773 
followed by Tukey´s multiple comparisons test for multiple groups comparisons. 774 
**P≤0.01 and ***P≤0.001 vs. Control+Veh; #P≤0.05 and ##P≤0.01 vs. EAM+Veh 775 
group.   776 
Figure 2. BML-111 treatment prevented the hypertrophy and fibrosis phenotype in 777 
EAM mice. Heart weight to body weight ratio (HW/BW) (a) and heart weight to tibial 778 
length (HW/TL) (b) determination from all experimental groups.  n=24. (c) BNP 779 
quantification in murine plasma at day 21 from all experimental groups. n=24. (d, e) 780 
Analysis of Anp (d) or Tgfb1, Col1a1 and Col3a1 (e) mRNA levels in cardiac tissue from 781 
all experimental groups at day 21. Graph represents the fold induction (FI) of each 782 
experimental group using Rplp0 as endogenous control. n≥22 (Tgfb), n≥17 (Col1a1), 783 
n≥16 (Col3a1). Dots represent individual data points. Graphs depict mean ± SD. 784 
Statistical significance was determined using one-way ANOVA followed by Tukey´s 785 
multiple comparisons test for multiple groups comparisons. **P≤0.01 and ***P≤0.001 786 
vs. Control+Veh; ###P≤0.001 vs. EAM+Veh group. 787 
Figure 3. Apoptosis of cardiac cells in EAM was reduced after BML-111 treatment. 788 
(a) Representative images of TUNEL staining performed in cardiac tissue from all 789 
experimental groups.  TUNEL-positive nuclei are stained in green and DAPI in blue. 790 




SD. Objective lens 20X. n≥8.  (b) Representative immunofluorescence images of cardiac 792 
tissue from all experimental groups stained with cleaved-caspase 3 in red, α-actinin in 793 
green and DAPI in blue. Values indicated in each image correspond to fluorescence 794 
quantification in relative fluorescence units (r.f.u.) ± SD. n≥7. Objective lens 63X. (c) 795 
Representative western blot images (left panel) and their corresponding quantification 796 
(right panel) of Bcl-2 and EndoG protein levels in cardiac tissue from all experimental 797 
groups. Normalization was performed using GAPDH as reference. n≥8 (Bcl-2), n≥5 798 
(EndoG). Dots represent individual data points. Graphs represent mean ± SD. Statistical 799 
significance was determined using one-way ANOVA followed by Tukey´s multiple 800 
comparisons test for multiple groups comparisons. *P≤0.05 and ***P≤0.001 vs. 801 
Control+Veh; #P≤0.05 and ###P≤0.001 vs. EAM+Veh group.   802 
Figure 4. Treatment of EAM mice with BML-111 reduced the cardiac oxidative 803 
stress by reducing Keap1 levels. (a, b) Determination of (a) oxidative DNA damage by 804 
measuring 8-OHdG fluorescent marker and (b) lipid peroxidation by measuring MDA 805 
fluorescent staining in cardiac tissue from all experimental groups. n≥5. (c) 806 
Representative immunofluorescence images of cardiac tissue from all experimental 807 
groups stained with Keap1 in red and DAPI in blue. Values indicated in each image 808 
correspond to fluorescence quantification in relative fluorescence units (r.f.u.) ± SD. 809 
Objective lens 63X. n≥4. (d) Representative western blot images (left panel) and their 810 
corresponding quantification (right panel) of Keap1 protein levels in cardiac tissue from 811 
all experimental groups. Normalization was performed using GAPDH as reference. n≥4. 812 
Dots represent individual data points. Graphs represent mean ± SD. Statistical 813 
significance was determined using one-way ANOVA followed by Tukey´s multiple 814 
comparisons test for multiple groups comparisons. *P≤0.05, **P≤0.01 and ***P≤0.001 815 
vs. Control+Veh; #P≤0.05 and ###P≤0.001 vs. EAM+Veh group.   816 
Figure 5. BML-111 induced Nrf2 antioxidant pathway activation in the heart. (a) 817 
Representative western blot images (left panel) and their corresponding quantification 818 
(right panel) of Nrf2 nuclear levels in cardiac tissue from mice treated with BML-111 for 819 
the indicated times. Normalization was performed using Lamin B as reference. n≥5. 820 
Statistical significance was determined using one-way ANOVA followed by Tukey´s 821 
multiple comparisons test for multiple groups comparisons. *P≤0.05, **P≤0.01 vs. 822 
control group. (b) Representative western blot images (left panel) and their corresponding 823 




cardiac tissue from mice treated with BML-111 for 24 h. Normalization was performed 825 
using Vinculin as reference. n≥4 (HO-1, NQO1 and Catalase) and n≥3 (PRDX-1). Dots 826 
represent individual data points. Graphs represent mean ± SD. Statistical significance was 827 
determined using unpaired Student´s t test. *P≤0.05, **P≤0.01 vs. control group. 828 
Figure 6. Nrf2 upstream signaling is mediated by sequential activation of several 829 
kinases in response to BML-111 challenge. (a) Representative western blot images (left 830 
panel) and their corresponding quantification (right panel) of CaMKK2, P-AMPKα and 831 
AMPKα protein levels HL-1 cells treated with BML-111 for the indicated times. 832 
Normalization was performed using Vinculin as reference. n≥8. (b) Representative 833 
western blot images (left panel) and their corresponding quantification (right panel) of 834 
Nrf2 nuclear levels in HL-1 cells treated with BML-111 and/or Compound C for the 835 
indicated times. Normalization was performed using Lamin B as reference. n≥4. Dots 836 
represent individual data points. Graphs represent mean ± SD. Statistical significance was 837 
determined using one-way ANOVA followed by Tukey´s multiple comparisons test for 838 
multiple groups comparisons. *P≤0.05, **P≤0.01, ***P≤0.001 vs. control group. 839 
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